Le et al.’s phase II trial compared response to programmed cell death 1 (PD-1) blockade with pembrolizumab in 41 patients with dMMR colorectal adenocarcinomas (11 patients, the majority of whom had received ≥2 chemotherapy regimens), proficient MMR (pMMR) colorectal adenocarcinomas (21 patients) and dMMR non-colorectal cancers (9 patients with predominantly GI cancers). This evidence concerns the gene PDCD1 and colorectal adenocarcinoma.